DMAC
DiaMedica Therapeutics Inc

1,556
Mkt Cap
$379.12M
Volume
1,351.00
52W High
$10.42
52W Low
$3.19
PE Ratio
-10.15
DMAC Fundamentals
Price
$7.18
Prev Close
$7.28
Open
$7.29
50D MA
$8.16
Beta
1.22
Avg. Volume
178,039.27
EPS (Annual)
-$0.605
P/B
7.34
Rev/Employee
$0.00
$175.59
Loading...
Loading...
News
all
press releases
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC
Cooperman Leon G lifted its holdings in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) by 98.2% in the third quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire·12d ago
News Placeholder
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat...
MarketBeat·13d ago
News Placeholder
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.1% - Time to Sell?
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 2.1% - Here's What Happened...
MarketBeat·14d ago
News Placeholder
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire·21d ago
News Placeholder
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8%
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest...
MarketBeat·2mo ago
News Placeholder
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire·2mo ago
News Placeholder
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from Brokerages
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat.com reports...
MarketBeat·2mo ago
<
1
2
...
>

Latest DMAC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.